Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Depressive syndromes during schizophrenic psychoses].

P Müller

    Fortschritte Der Medizin
    |August 10, 1978
    PubMed
    Summary

    Depression is common in schizophrenia. A key finding is that neuroleptic drugs can cause severe depression, best treated by reducing or stopping the medication.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Protective effect of ranitidine in the stomach and duodenum against piroxicam. An endoscopy controlled double-blind study].

    Arzneimittel-Forschung·1992
    Same author

    [High-dose ranitidine protects stomach and duodenum completely against piroxicam. An endoscopic double-blind pilot study].

    Zeitschrift fur Gastroenterologie·1992
    Same author

    Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?

    International journal of clinical pharmacology, therapy, and toxicology·1992
    Same author

    [Hypohidrotic ectodermal dysplasia as the cause of recurrent hyperthermia in a young infant].

    Kinderarztliche Praxis·1992
    Same author

    Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients.

    Zeitschrift fur Gastroenterologie·1992
    Same author

    Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification.

    The British journal of psychiatry. Supplement·1992

    Area of Science:

    • Psychiatry
    • Clinical Psychology
    • Pharmacology

    Context:

    • Depressive syndromes frequently co-occur with schizophrenia, presenting diagnostic and therapeutic challenges.
    • Understanding the distinct origins of depression in schizophrenic patients is crucial for effective management.
    • Previous research highlights the complexity of mood disorders within the schizophrenic spectrum.

    Purpose:

    • To differentiate and characterize three primary forms of depressive syndromes observed in schizophrenia.
    • To investigate the etiology and identify optimal treatment strategies for pharmacogenic depressions in schizophrenic patients.
    • To evaluate the efficacy of neuroleptic dose reduction and adjunctive therapies for depression.

    Summary:

    • Three forms of depression in schizophrenia are identified: acute psychotic reactions (neuroleptic therapy), post-psychosis mood (psychotherapy), and pharmacogenic depression (neuroleptic-induced).
    • Pharmacogenic depression, often severe and linked to neuroleptic use (e.g., fluphenazine-decanoate), affects a significant portion of patients.
    • Controlled studies confirm neuroleptics as the cause of pharmacogenic depression, with dose reduction or discontinuation as the primary treatment. Intravenous antiparkinsonian drugs offer rapid relief, and antidepressants may accelerate recovery.

    Impact:

    • This research clarifies the differential diagnosis of depression in schizophrenia, improving patient care.
    • It establishes neuroleptic dose adjustment as a primary therapeutic strategy for pharmacogenic depression, reducing iatrogenic harm.
    • Findings guide clinicians in selecting appropriate interventions, potentially improving outcomes and quality of life for schizophrenic patients experiencing depression.

    Related Experiment Videos